Yuan Wang1, Lan-Lan Feng2, Pei-Gang Ji1, Jing-Hui Liu1, Shao-Chun Guo1, Yu-Long Zhai1, Eric W Sankey3, Yue Wang4, Yan-Rong Xue5,6, Na Wang1, Miao Lou1, Meng Xu1, Min Chao1, Guo-Dong Gao1, Yan Qu1, Li Gong2, Liang Wang1. 1. Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. 2. Department of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. 3. Department of Neurosurgery, Duke University Hospital, Durham, NC, United States. 4. Department of Health Statistics, Fourth Military Medical University, Xi'an, China. 5. National Time Service Center, Chinese Academy of Sciences, Xi'an, China. 6. School of Optoelectronics, University of Chinese Academy of Sciences, Beijing, China.
Abstract
PURPOSE: Diffuse midline gliomas (DMG) with H3K27M mutations have been identified as a rare distinctive entity with unique genetic features, varied molecular alterations, and poor prognosis. The current study aimed to evaluate the clinical characteristics and profile of molecular markers on patients with a DMG harboring H3K27M mutations, and explore the impact of this genetic makeup on overall survival. METHODS: We retrospectively analyzed 43 consecutive patients diagnosed with a DMG harboring H3K27M mutations (age range 3 to 75 years) and treated in a tertiary institution within China between January 2017 to December 2019. Various clinical and molecular factors were evaluated to assess their prognostic value in this unique patient cohort. RESULTS: The median overall survival (OS) was 12.83 months. Preoperative Karnofsky Performance Score (KPS) and adjuvant radiotherapy were found to be independent clinical parameters influencing the OS by multivariate analysis (p = 0.027 and p < 0.001 respectively). Whereas extent of tumor resection failed to demonstrate statistical significance. For molecular markers, P53 overexpression was identified as a negative prognostic factor for overall survival by multivariate analysis (p = 0.030). CONCLUSION: Low preoperative KPS, absence of radiotherapy and P53 overexpression were identified as predictors of a dismal overall survival in patients with DMG and H3K27M mutations.
PURPOSE: Diffuse midline gliomas (DMG) with H3K27M mutations have been identified as a rare distinctive entity with unique genetic features, varied molecular alterations, and poor prognosis. The current study aimed to evaluate the clinical characteristics and profile of molecular markers on patients with a DMG harboring H3K27M mutations, and explore the impact of this genetic makeup on overall survival. METHODS: We retrospectively analyzed 43 consecutive patients diagnosed with a DMG harboring H3K27M mutations (age range 3 to 75 years) and treated in a tertiary institution within China between January 2017 to December 2019. Various clinical and molecular factors were evaluated to assess their prognostic value in this unique patient cohort. RESULTS: The median overall survival (OS) was 12.83 months. Preoperative Karnofsky Performance Score (KPS) and adjuvant radiotherapy were found to be independent clinical parameters influencing the OS by multivariate analysis (p = 0.027 and p < 0.001 respectively). Whereas extent of tumor resection failed to demonstrate statistical significance. For molecular markers, P53 overexpression was identified as a negative prognostic factor for overall survival by multivariate analysis (p = 0.030). CONCLUSION: Low preoperative KPS, absence of radiotherapy and P53 overexpression were identified as predictors of a dismal overall survival in patients with DMG and H3K27M mutations.
Authors: Eshini Panditharatna; Lindsay B Kilburn; Mariam S Aboian; Madhuri Kambhampati; Heather Gordish-Dressman; Suresh N Magge; Nalin Gupta; John S Myseros; Eugene I Hwang; Cassie Kline; John R Crawford; Katherine E Warren; Soonmee Cha; Winnie S Liang; Michael E Berens; Roger J Packer; Adam C Resnick; Michael Prados; Sabine Mueller; Javad Nazarian Journal: Clin Cancer Res Date: 2018-10-15 Impact factor: 12.531
Authors: Michael Karremann; Gerrit H Gielen; Marion Hoffmann; Maria Wiese; Niclas Colditz; Monika Warmuth-Metz; Brigitte Bison; Alexander Claviez; Dannis G van Vuurden; André O von Bueren; Marco Gessi; Ingrid Kühnle; Volkmar H Hans; Martin Benesch; Dominik Sturm; Rolf-Dieter Kortmann; Andreas Waha; Torsten Pietsch; Christof M Kramm Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Huy Gia Vuong; Hieu Trong Le; Tam N M Ngo; Kar-Ming Fung; James D Battiste; Rene McNall-Knapp; Ian F Dunn Journal: J Neurooncol Date: 2021-11-18 Impact factor: 4.130
Authors: Huy Gia Vuong; Tam N M Ngo; Hieu Trong Le; Andrew Jea; Maya Hrachova; James Battiste; Rene McNall-Knapp; Ian F Dunn Journal: Front Oncol Date: 2022-03-18 Impact factor: 6.244